BPCR — Biopharma Credit Income Statement
0.000.00%
Last trade - 00:00
- $1.07bn
- $986.41m
- $135.73m
- 70
- 79
- 65
- 85
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 151 | 110 | 104 | 218 | 136 |
Cost of Revenue | |||||
Gross Profit | 123 | 91.4 | 88 | 184 | 110 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.6 | 20.9 | 18.9 | 35.8 | 27.3 |
Operating Profit | 122 | 89.1 | 85 | 182 | 108 |
Net Income Before Taxes | 122 | 89.1 | 85 | 182 | 108 |
Provision for Income Taxes | |||||
Net Income After Taxes | 122 | 89.1 | 85 | 182 | 108 |
Net Income Before Extraordinary Items | |||||
Net Income | 122 | 89.1 | 85 | 182 | 108 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 122 | 89.1 | 85 | 182 | 108 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.088 | 0.065 | 0.062 | 0.134 | 0.083 |
Dividends per Share | |||||
Special Dividends per Share |